Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Medtronic
AstraZeneca
Baxter
Express Scripts

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

AVANDIA Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Avandia patents expire, and what generic alternatives are available?

Avandia is a drug marketed by Sb Pharmco and is included in one NDA. There is one patent protecting this drug.

This drug has forty-five patent family members in thirty-six countries.

The generic ingredient in AVANDIA is rosiglitazone maleate. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the rosiglitazone maleate profile page.

Drug patent expirations by year for AVANDIA
Drug Prices for AVANDIA

See drug prices for AVANDIA

Recent Clinical Trials for AVANDIA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Dan ZandbergPhase 2
National University, SingaporePhase 4
Agency for Science, Technology and ResearchPhase 4

See all AVANDIA clinical trials

Synonyms for AVANDIA
(+/-)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione
(RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion
122320-73-4
2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-
2,4-thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-
2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI)
2,4-Thiazolidinedione, 5-004-02-((((methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-
20R734
4CA-1110
5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate
5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione
5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione
5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione
5-[[4-[2-(methyl-(2-pyridyl)amino)ethoxy]phenyl]methyl] thiazolidine-2,4-dione
5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-2,4-thiazolidinedione
5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]-phenyl]methyl]-2,4-thiazolidine-dione
5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione
5-[[4-[2-(methyl-pyridin-2-ylamino)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
5-[[4-[2-[methyl(2-pyridyl)amino]ethoxy]phenyl]methyl]thiazolidine-2,4-dione
5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione
5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4dione
5-[4-[2-[Methyl(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione
5-[4-[2-[N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]phenyl methyl]thiazolidine-2,4-dione
6P-065
AB0011992
AB00698473_20
AB00698473_21
AB00698473_22
AB00698473_23
AB00698473-15
AB00698473-17
AB00698473-18
AB00698473-19
AB2000652
AC-3459
AC1L2U9N
ACT04332
AK-72839
AKOS015894872
AN-12970
ANW-44906
API0006964
Avandamet
Avandaryl
Avandia;BRL-49653
AX8017813
BBL029079
BCP03047
BCP0726000232
BCP9000017
BDBM50030474
BG0432
BR-72839
BRD-A97437073-001-02-3
BRD-A97437073-001-03-1
BRD-A97437073-001-04-9
Brl 49653
BRL 49653; Rezult; Rosiglizole; TDZ 01
Brl-49653
BRL49653
BSPBio_002693
C-20817
C18H19N3O3S
CAS-122320-73-4
CC-34292
CCG-39102
CHEBI:50122
CS-1088
CTK8B4395
D08491
DB00412
DSSTox_CID_17131
DSSTox_GSID_37131
DSSTox_RID_79303
DTXSID7037131
FT-0602578
Gaudil (TN)
GP6434
GTPL1056
HMS1922J11
HMS2094O13
HMS3649G08
HMS3656K16
HSDB 7555
HY-17386
I06-0141
IDMB (1uM BRL49653, 1uM Dexamethasone, 0.5uM IBMX, 10ug/mL Insulin)
J10213
KBio2_002183
KBio2_004751
KBio2_007319
KBio3_001913
KBioGR_001609
KBioSS_002183
KS-00000IPU
KSC914G9L
LS-151340
MCULE-8293284864
MFCD00871760
MolPort-002-508-212
MP-0331
NCGC00095124-01
NCGC00095124-02
NCGC00095124-03
NCGC00095124-04
NCGC00095124-05
NCGC00095124-06
NCGC00095124-08
NSC-758698
NSC758698
Pharmakon1600-01504263
Q-201681
R0106
Rosi
Rosigilitazone
Rosigliazone maleate
Rosiglitazon
rosiglitazona
rosiglitazone
rosiglitazone (Avandia)
Rosiglitazone (INN)
Rosiglitazone [INN:BAN]
Rosiglitazone base
Rosiglitazone, >=98% (HPLC)
rosiglitazonum
Rosiglizole
RTC-064102
S00306
S2556
SB17326
SC-19017
SCHEMBL14383595
SCHEMBL5169
SPBio_001142
Spectrum_001703
SPECTRUM1504263
Spectrum2_001241
Spectrum3_000997
Spectrum4_001125
Spectrum5_001464
SR-01000763023
SR-01000763023-12
SR-01000763023-5
SR-01000763023-6
ST24029274
STL350047
SW197573-6
TDZ 01
Tox21_111434
Tox21_111434_1
VA11695
YASAKCUCGLMORW-UHFFFAOYSA-N
Paragraph IV (Patent) Challenges for AVANDIA
Tradename Dosage Ingredient NDA Submissiondate
AVANDIA TABLET;ORAL rosiglitazone maleate 021071

US Patents and Regulatory Information for AVANDIA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sb Pharmco AVANDIA rosiglitazone maleate TABLET;ORAL 021071-002 May 25, 1999 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sb Pharmco AVANDIA rosiglitazone maleate TABLET;ORAL 021071-003 May 25, 1999 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sb Pharmco AVANDIA rosiglitazone maleate TABLET;ORAL 021071-004 May 25, 1999 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for AVANDIA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sb Pharmco AVANDIA rosiglitazone maleate TABLET;ORAL 021071-002 May 25, 1999   Start Trial   Start Trial
Sb Pharmco AVANDIA rosiglitazone maleate TABLET;ORAL 021071-003 May 25, 1999   Start Trial   Start Trial
Sb Pharmco AVANDIA rosiglitazone maleate TABLET;ORAL 021071-003 May 25, 1999   Start Trial   Start Trial
Sb Pharmco AVANDIA rosiglitazone maleate TABLET;ORAL 021071-004 May 25, 1999   Start Trial   Start Trial
Sb Pharmco AVANDIA rosiglitazone maleate TABLET;ORAL 021071-004 May 25, 1999   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for AVANDIA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0306228 SPC/GB01/002 United Kingdom   Start Trial PRODUCT NAME: 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE, "ROSIGLITAZONE" ITS TAUTOMERS, PHARMACEUTICALLY ACCEPTABLE SALTS, SUCH AS THE MALEATE, AND PHARMACEUTICALLY ACCEPTABLE SOLVATES.; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711
0658161 SPC/GB01/003 United Kingdom   Start Trial PRODUCT NAME: N-(4-(2(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE MALEIC ACID, "ROSIGLITAZONE MALEATE", ITS TAUTOMERS AND PHARMACEUTICALLY ACCEPTABLE SOLVATES; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711
0306228 38/2000 Austria   Start Trial PRODUCT NAME: ROSIGLITAZONE; NAT. REGISTRATION NO/DATE: EU/1/00/137/001 - EU/1/00/137/012 20000711; FIRST REGISTRATION: LI 55176 19990929
0306228 2001C/004 Belgium   Start Trial PRODUCT NAME: ROSIGLITAZONE; REGISTRATION NO/DATE: EU/1/00/137/001 20000717
0658161 C300035 Netherlands   Start Trial PRODUCT: ROSIGLITAZONE,MALEAAT, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR SOLVAAT.
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Baxter
Boehringer Ingelheim
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.